Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma

Acta Histochemica

Volumn 113, Issue 3, 2011, Pages 317-325

  Sanci, Muzaffer ^a   Dikis, Cihan ^a   Inan, Sevinc ^b   Turkoz, Elgin ^b   Dicle, Nilgun ^a   Ispahi, Cigdem ^a  

^a Ege Maternity Hospital   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Ki 67; Leiomyoma; Leiomyosarcoma; VEGF; VEGFR 1; VEGFR 2

Indexed keywords

AVIDIN; BIOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PARACRINE SIGNALING; TISSUE INTERACTION; TUMOR CELL; TUMOR VASCULARIZATION;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952009484     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2010.01.001     Document Type: Article

References (40)

1. Abulafia O., Sherer D. Angiogenesis of the endometrium. Obst Gyn 1999, 94:148-153.
2. Andersen J., Barbieri R.L. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Invest 1995, 2:663-672.
3. Arita S., Kikawa F., Kajiyama H., Shibata K., Kawaly M., Mizunoz K., et al. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Int J Gynecol Cancer 2005, 15:329-336.
4. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Tr 1994, 29:127-138.
5. Broome M.A., Hunter T. Requirement for c-Src catalytic activity and the SH3 domain in derived growth factor BB and epidermal growth factor mitogenic signaling. J Biol Chem 1996, 271:16798-16806.
6. Carpenter G., Cohen S. Epidermal growth factor. J Biol Chem 1990, 265:7709-7712.
7. de Jong J.S., van Diest P.J., van d Valk P., Baak J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Pathol 1998, 184:53-57.
8. Di Lieto A., De Falco M., Pollio F., Mansueto G., Salvatore G., Somma P., et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Invest 2005, 12:123-128.
9. Dixon D., He H., Haseman J.K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000, 108:795-802.
10. Emoto M., Iwasaki H., Ishiguro M., Kikuchi M., Horiuchi S., Saito T., et al. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and the expression of vascular endothelial growth factor between the epithelial and mesenchymal elements. Hum Pathol 1999, 30:1232-1241.
11. Folkman J. How is the blood vessel growth regulated in normal and neoplastic tissue?. Cancer Res 1986, 46:467-473.
12. Gadducci A., Viacava P., Cosio S., Cecchetti D., Fanelli G., Fanucchi A., et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003, 23:3001-3008.
13. Han Y., Zhou Y., Zheng S. Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus. Zhonghua Fu Chan Ke Za Zhi 2002, 37:539-541.
14. Hazelton D.A., Hamilton T.C. Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1999, 1:59-63.
15. Hong T., Shimada Y., Uchida S., Itami A., Li Z., Ding Y., et al. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001, 8:141-148.
16. Layfield L.J., Liu K., Dodge R., Barsky S.H. Uterine smooth muscle tumors: utility of classification by proliferation, ploidity, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med 2004, 124:221-227.
17. Maruo T., Ohara N., Wang J., Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004, 10:207-220.
18. Mayerhofer K., Lozanov P., Bodner K., Bodner-Adler B., Obermair A., Kimberger O., et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol Oncol 2004, 92:175-179.
19. Mayerhofer K., Lozanov P., Bodner K., Bodner-Adler B., Obermair A., Kimberger O., et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand 2004, 83:1085-1088.
20. Mittal K., Demopoulos I. mib-1 (Ki-67), p53, Estrogen Receptor, and Progesterone Receptor expression in uterine smooth muscle tumors. Hum Pathol 2001, 32:984-987.
21. Moore A.B., He H., Yoshida A., Rico P.J., Haseman J.K., Dixon D. Transforming growth factor - alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice. Exp Toxicol Pathol 2005, 52:195-200.
22. Nelson K.G., Takahashi T., Bossert N.L., Walmer D.K., McLachlan J.A. Epidermal growth factor replaces estrogen in the stimulation of female genital tract growth and differentiation. Proc Natl Acad Sci USA 1991, 88:21-25.
23. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
24. Norris H.J., Zaloudek C.J. Mesenchymal tumors of the uterus. Pathology of the Female Genital Tract 1982, 352-392. Springer Verlag, New York. Second ed. R.J. Kuman, A. Blaustein (Eds.).
25. Page V., Cote M., Rancourt C., Sullivan M., Piche A. BAG-1 p29 protein prevents drug-induced cell death in the presence of EGF and enhances resistance to anoikis in KOV3 human ovarian cancer cells. Biochem Biophys Res Commun 2005, 328:874-884.
26. Potti A., Ganti A.K., Foster H., Knox S., Hebert B.J., Tendulkar K., et al. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 2004, 24:333-337.
27. Prigent S.A., Lemoine N.R. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992, 4:1-24.
28. Rein M.S., Nowak R.A. Biology of uterine myomas and myometrium in vitro. Seminars in Reproductive Endocrinology 1992, 310-319. Thieme, New York. R.L. Barbieri (Ed.).
29. Robboy S.J., Bentley R.C., Butnor K., Anderson M.C. Pathology and pathophysiology of uterine smooth muscle tumors. Environ Health Perspect 2000, 108:779-784.
30. Rossi M.J., Chegini N., Masterson B.J. Presence of epidermal growth factor, platelet-derived growth factor and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992, 130:1716-1727.
31. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
32. Shimomura Y., Matsuo H., Samoto T., Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998, 83:2192-2198.
33. Sonoda T., Kobayashi H., Kaku T., Hirakawa T., Nakano H. Expression of angiogenesis factors in monolayer culture, multicellular spheroid and in vivo transplanted tumor by human ovarian cancer cell lines. Cancer 2003, 10:229-237.
34. Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., Smith S.K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997, 77:607-614.
35. Tanir H.M., Ozalp S., Yalcin O.T., Colak O., Akcay A., Senses T. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol 2003, 24:271-274.
36. Tsai S.J., Lin S.J., Cheng Y.M., Chen H.M., Wing LYC Expression and functional analysis of pituitary tumor transforming growth factor-1 in uterine leiomyomas. J Clin Endocrinol Metab 2005, 90:3715-3723.
37. Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin Obstet Gynaecol 1998, 12:169-176.
38. Wang J., Ohara N., Takekida S., Xu Q., Maruo T. Comparative effects of heparin-binding epidermal growth factor-like growth factor on the growth of cultured human uterine leiomyoma cells and myometrial cells. Hum Reprod 2005, 20:1456-1465.
39. Wright J.D., Reuter C.W., Weber M.J. An incomplete program of cellular tyrosine phosphorylations by kinase-defective epidermal growth factor receptors. J Biol Chem 1995, 270:12085-12093.
40. Zeren T., Inan S., Vatansever H.S., Ekerbicer N., Sayhan S. Significance of tyrosine kinase activity on malign transformation of ovarian tumors: a comparison between EGF-R and TGF α. Acta Histochem 2008, 110:256-263.